MON4STRAT

"Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance"

Coordinatore	UNIVERSITE DE LIEGE    more  Organization address city: LIEGE postcode: 4000 contact info Titolo: Ms. Nome: Isabelle Cognome: Halleux Email: send email Telefono: +32 43665428 Fax: +32 43665558
Nazionalità Coordinatore	Belgium [BE]
Totale costo	7˙861˙595 €
EC contributo	5˙988˙941 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-02-01   -   2018-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITE DE LIEGE  Organization address city: LIEGE postcode: 4000 contact info Titolo: Ms. Nome: Isabelle Cognome: Halleux Email: send email Telefono: +32 43665428 Fax: +32 43665558	BE (LIEGE)	coordinator	1˙312˙523.00
2	UNIVERSITE CATHOLIQUE DE LOUVAIN  Organization address address: Place De L'Universite 1 city: LOUVAIN LA NEUVE postcode: 1348 contact info Titolo: Prof. Nome: Francoise Cognome: Vanbambeke Email: send email Telefono: +32 27647378	BE (LOUVAIN LA NEUVE)	participant	905˙600.00
3	WOW TECHNOLOGY  Organization address address: RUE PIEDS D'ALOUETTE 18 city: NANINNE postcode: 5100 contact info Titolo: Mr. Nome: Jean Cognome: Demarteau Email: send email Telefono: +32 81719740 Fax: +32 81 40 24 44	BE (NANINNE)	participant	869˙407.00
4	SERVICIO MADRILENO DE SALUD  Organization address address: PLAZA CARLOS TRIAS BERTRAN 7 city: MADRID postcode: 28020 contact info Titolo: Mr. Nome: José Ignacio Cognome: Flores Nicolás Email: send email Telefono: +34 913368147	ES (MADRID)	participant	563˙302.00
5	UNIVERSITE LIBRE DE BRUXELLES  Organization address address: Avenue Franklin Roosevelt 50 city: BRUXELLES postcode: 1050 contact info Titolo: Dr. Nome: Christine Cognome: Courillon Email: send email Telefono: +32 2 6506718 Fax: +32 2 6502321	BE (BRUXELLES)	participant	406˙850.00
6	UNIVERSITY OF HOUSTON SYSTEM  Organization address address: EZEKIEL CULLEN BUILDING 203 city: HOUSTON postcode: 772042022 contact info Nome: Beverly Cognome: Rymer Email: send email Telefono: +1 7137435773	US (HOUSTON)	participant	400˙600.00
7	INST CARDIOMETABOLISME NUTRITION ICAN  Organization address address: BOULEVARD DE L'HOPITAL 47-83 city: PARIS postcode: 75013 contact info Titolo: Prof. Nome: Jean Cognome: Chastre Email: send email Telefono: +33 142163822	FR (PARIS)	participant	385˙151.00
8	AEPODIA SA  Organization address address: RUE LOUIS DE GEER 6 city: OTTIGNIES LOUVAIN LA NEUVE postcode: 1348 contact info Titolo: Dr. Nome: Denis Cognome: Gossen Email: send email Telefono: 3210392007	BE (OTTIGNIES LOUVAIN LA NEUVE)	participant	371˙504.00
9	CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE  Organization address address: AVENUE OSCAR LAMBRET 2 city: LILLE postcode: 59037 contact info Titolo: Dr. Nome: Bernadette Cognome: Lucas Email: send email Telefono: +33 320446959 Fax: +33 320446630	FR (LILLE)	participant	315˙752.00
10	TARTU ULIKOOL  Organization address address: ULIKOOLI 18 city: TARTU postcode: 50090 contact info Titolo: Prof. Nome: Irja Cognome: Lutsar Email: send email Telefono: +372 7374171 Fax: +372 7374172	EE (TARTU)	participant	315˙752.00
11	SGS EXPRIMO NV  Organization address address: GENERAAL DE WITTELAAN 19A city: MECHELEN postcode: 2800 contact info Titolo: Dr. Nome: Philippe Cognome: Jacqmin Email: send email Telefono: +32 82677608 Fax: +32 82677609	BE (MECHELEN)	participant	142˙500.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Stratified clinical treatment interventions meeting patient-specific efficacy (pharmacodynamics) while at the same time lowering the risk of emergence of drug resistance (EDR) and minimizing adverse effects are particularly needed in Hospital-acquired and Ventilator-Associated pneumonia [HAP/VAP] where morbidity, mortality and health care costs remain high. β-lactam antibiotics are at the cornerstone of most effective treatments of HAP/VAP, but dosage adaptations remain difficult because available models (i) focus mainly on efficacy (neglecting EDR and dose-related side effects) and (ii) are derived from population data which imperfectly fit individual patient’s needs due to large, rapid and difficult-to-predict variations of blood levels. Current methods for monitoring β-lactam blood levels are slow and require complex instruments not usable at bed-side. Yet, generating easily, rapidly and cost-effectively real data usable at the patient’s bed-side should improve outcomes of β-lactam treatments. This is what 3 out of the 11 partners of the MON4STRAT consortium have recently developed (patent pending). Thus the objective of the Project is to integrate both (i) state-of-the-art PK/PD and EDR profiles AND (ii) real-time/patient-specific free β-lactam blood levels monitored at the patient’s bed-side according to the patented assay for developing and implementing a new approach to (i) stratify the HAP/VAP patients according to their specific response, (ii) to propose immediately applicable dose adjustments during treatment and thus (iii) to improve efficacy while reducing risk of EDR or adverse effects. The MON4STRAT approach will be validated through a prospective, multicentre, randomized clinical trial with150 adults. Its applicability in paediatrics will be tested through an observational study with 70 children/neonates. Being generic in nature, MON4STRAT will be replicable to other infectious conditions.'